Holen Sie sich die Stockscreener-App
4.86
1.82%
-0.09
Handel nachbörslich:
4.86
Journey Medical Corp Aktie (DERM) Neueste Nachrichten
Wasatch Advisors holds 2.13M Journey Medical (NASDAQ: DERM) — 10% stake - stocktitan.net
Stock List: Research Stocks from Around the World - GuruFocus
DERM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
US Stocks Recap: Can Journey Medical Corporation be the next market leaderPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Short Squeeze: Can Journey Medical Corporation reach all time highs this year2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks - Yahoo Finance
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Update: Can Journey Medical Corporation reach all time highs this yearWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - marketbeat.com
Journey Medical Corporation (NASDAQ:DERM) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Forecasts Journey Medical Q1 Earnings - MarketBeat
Market Pulse: What hedge funds are buying Journey Medical CorporationQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Journey Medical Corp (DERM) - The Globe and Mail
Journey Medical (DERM) Q4 Results: Examining Essential Metrics Compared to Projections - Bitget
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intellectual Property Overview - Minichart
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Journey Medical Corporation Q4 2025 Earnings Call Summary - finance.yahoo.com
HC Wainwright Reaffirms Buy Rating for Journey Medical (NASDAQ:DERM) - marketbeat.com
Journey Medical stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Journey Medical 2025 10-K: $61.9M Revenue, $(11.4)M Net Loss - TradingView
Journey Medical earnings missed by $0.50, revenue fell short of estimates - Investing.com South Africa
Journey Medical Corp (DERM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
DERM Drops 25%: The Contradiction of a Positive Analyst Rating During Sharp Intraday Decline - Bitget
Earnings call transcript: Journey Medical reports Q4 2025 growth, EMROSI sales boost - uk.investing.com
Journey Medical Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Journey Medical reports Q4 2025 growth, EMROSI sales boost By Investing.com - Investing.com South Africa
Journey Medical Corp reports results for the quarter ended September 30Earnings Summary - TradingView
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Journey Medical (Nasdaq: DERM) adds Emrosi rosacea drug and global deals - Stock Titan
Journey posts FY2025 revenue $61.9M, narrowed net loss to $11.4M and reports $2.9M Adjusted EBITDA - TradingView
Journey Medical (NASDAQ: DERM) grows 2025 revenue to $61.9M as losses narrow - stocktitan.net
New rosacea drug drove $14.7M for Journey Medical after April launch - Stock Titan
Rate Cut: Is Journey Medical Corporation undervalued by DCF analysis2026 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Earnings Scheduled For March 25, 2026 - Benzinga
Journey Medical Corp stock faces key test ahead of Q4 2025 earnings release on March 25, 2026 - AD HOC NEWS
Journey Medical Corp (DERM) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Journey Medical Corp expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Pullback Watch: Is Journey Medical Corporation undervalued by DCF analysisWeekly Investment Recap & Capital Protection Trading Alerts - baoquankhu1.vn
Danone Sets New Sustainability Targets with Second Phase of Impact Journey - Food & Beverage Outlook
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - The Manila Times
WallabyPhenox Restructures Debt and Accelerates Global Growth - The Manila Times
Off The Hook Yachts Expands Mid-Atlantic Presence with Strategic Waterfront Hub to Increase Inventory Velocity and Margin Capture - The Manila Times
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available - The Manila Times
GSI Technology Concludes Strategic Alternatives Review - The Manila Times
Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25 - Stock Titan
Journey Medical (DERM) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
DERM Stock Price, Quote & Chart | JOURNEY MEDICAL CORP (NASDAQ:DERM) - ChartMill
DERM SEC FilingsJourney Medical Corp 10-K, 10-Q, 8-K Forms - stocktitan.net
Rally Mode: Will Journey Medical Corporation benefit from sector rotationJuly 2025 Macro Moves & Entry Point Confirmation Alerts - baoquankhu1.vn
Journey Medical (NASDAQ:DERM) Shares Down 3.5%What's Next? - marketbeat.com
Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (CLPT) and Journey Medical Corp (DERM) - The Globe and Mail
10 Best Travel Insurance Companies For 2026 - Forbes
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):